Track topics on Twitter Track topics that are important to you
The use of continuous glucose monitoring (CGM) has been increasing, especially in patients with type 1 diabetes, partly due to improved accuracy with lower mean amplitude relative difference (about 10%) with the newer or implantable sensors.1,2 Most real-time subcutaneous sensors are approved for 7 days—except for the implantable sensor, which lasts 3 months—and require two calibrations per day.1–3 One on-demand sensor is approved for 14 days and needs no calibrations.2 Improved health outcomes, such as increased time in target and reduced hypoglycaemia, diabetic ketoacidosis, and glucose variability, and improved glucose control are reported with use of CGM in non-pregnant patients using multiple daily injections or insulin pumps.NEXT ARTICLE
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...